DE69428969T2 - Impfstoff geeignet eine Immunantwort gegen N-Glycolysierte-Gangliosiden hervorzurufen und ihre Anwendung als Antikrebsmittel - Google Patents

Impfstoff geeignet eine Immunantwort gegen N-Glycolysierte-Gangliosiden hervorzurufen und ihre Anwendung als Antikrebsmittel

Info

Publication number
DE69428969T2
DE69428969T2 DE69428969T DE69428969T DE69428969T2 DE 69428969 T2 DE69428969 T2 DE 69428969T2 DE 69428969 T DE69428969 T DE 69428969T DE 69428969 T DE69428969 T DE 69428969T DE 69428969 T2 DE69428969 T2 DE 69428969T2
Authority
DE
Germany
Prior art keywords
glycolysed
gangliosides
eliciting
vaccine
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69428969T
Other languages
English (en)
Other versions
DE69428969D1 (de
Inventor
Rolando Perez Rodriguez
Luis Enrique Fernandez Molina
Gilda Marquina Rodriguez
Adriana C Perez
Oscar Gonzalo Valien Hernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Immunologia Molecular
Original Assignee
Centro de Immunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Immunologia Molecular filed Critical Centro de Immunologia Molecular
Publication of DE69428969D1 publication Critical patent/DE69428969D1/de
Application granted granted Critical
Publication of DE69428969T2 publication Critical patent/DE69428969T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69428969T 1993-12-29 1994-12-22 Impfstoff geeignet eine Immunantwort gegen N-Glycolysierte-Gangliosiden hervorzurufen und ihre Anwendung als Antikrebsmittel Expired - Lifetime DE69428969T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU92131A CU22420A1 (es) 1993-12-29 1993-12-29 Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer

Publications (2)

Publication Number Publication Date
DE69428969D1 DE69428969D1 (de) 2001-12-13
DE69428969T2 true DE69428969T2 (de) 2002-08-22

Family

ID=45992881

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69428969T Expired - Lifetime DE69428969T2 (de) 1993-12-29 1994-12-22 Impfstoff geeignet eine Immunantwort gegen N-Glycolysierte-Gangliosiden hervorzurufen und ihre Anwendung als Antikrebsmittel

Country Status (9)

Country Link
US (1) US5788985A (de)
EP (1) EP0661061B1 (de)
JP (1) JP3044173B2 (de)
CN (2) CN1099894C (de)
CA (1) CA2139217C (de)
CU (1) CU22420A1 (de)
DE (1) DE69428969T2 (de)
ES (1) ES2168287T3 (de)
HK (1) HK1048942A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22702A1 (es) * 1997-10-21 2001-07-31 Centro Inmunologia Molecular Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen
US6149921A (en) * 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
US5977316A (en) * 1995-01-17 1999-11-02 The Board Of Trustees Of The University Of Kentucky Monoclonal antibody 1A7 and related polypeptides
US5935821A (en) 1995-01-17 1999-08-10 Board Of Trustees Of The University Of Kentucky Polynucleotides related to monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
US5612030A (en) 1995-01-17 1997-03-18 University Of Kentucky Research Foundation Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
US7341994B2 (en) 2000-04-25 2008-03-11 Otsuka Pharmaceutical Co., Ltd. GD3-mimetic peptides
PE20020572A1 (es) 2000-12-06 2002-07-31 Centro Inmunologia Molecular Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
CU23257A1 (es) * 2003-02-27 2008-01-24 Centro Inmunologia Molecular COMPOSICIONES VACUNALES A BASE DE GANGLIOSIDOS PARA LA ADMINISTRACION SUBCUTáNEA
BR112012004689A2 (pt) 2009-09-01 2019-09-24 Lz Therapeutics Inc métodos para extração e purificação de gangliosídeos.
WO2011146804A2 (en) * 2010-05-20 2011-11-24 Lazarus Therapeutics, Inc. Gm3 ganglioside replacement therapy
CU24070B1 (es) * 2011-12-27 2015-01-29 Ct De Inmunología Molecular Composiciones farmacéuticas para el tratamiento de tumores que expresan regf y gangliósidos n-glicolilados gm3 (neugcgm3)
JP2015511120A (ja) 2012-01-20 2015-04-16 ガーネット バイオセラピューティクス インコーポレイテッド ガングリオシド産生の方法
CU20170173A7 (es) * 2017-12-27 2019-11-04 Ct Inmunologia Molecular Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US4965198A (en) * 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
AU603585B2 (en) * 1986-05-07 1990-11-22 Sloan-Kettering Institute For Cancer Research Vaccine for stimulating or enhancing production of antibodies directed against GM2
NZ222192A (en) * 1986-10-20 1991-03-26 Kanto Ishi Pharma Co Ltd Glycolipid containing n-glycolylneuraminic acid, and preparation thereof
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
US5026557A (en) * 1987-09-09 1991-06-25 The Liposome Company, Inc. Adjuvant composition
US5102663A (en) * 1988-10-18 1992-04-07 Sloan-Kettering Instutute For Cancer Research Vaccine for stimulating or enhancing production of antibodies against 9-O-acetyl GD3
ES2207768T3 (es) * 1989-05-25 2004-06-01 Sloan-Kettering Institute For Cancer Research Anticuerpo anti-idiotipo que inducen a una respuesta inmune contra un glicoesfingolipido y su uso.
ATE198834T1 (de) * 1991-03-12 2001-02-15 Us Health Konjugate bestehend aus polysaccharid und protein
EP0586002B1 (de) * 1992-08-18 2000-01-19 CENTRO de IMMUNOLOGIA MOLECULAR Monoklonale Antikörper gegen den epidermalen Wachstumsfaktorrezeptor, Zellen und Verfahren zur ihrer Herstellung und sie erhaltende Zusammensetzungen
AU685776B2 (en) * 1993-01-22 1998-01-29 Sloan-Kettering Institute For Cancer Research Ganglioside-KLH conjugate vaccines with QS-21

Also Published As

Publication number Publication date
ES2168287T3 (es) 2002-06-16
EP0661061A3 (de) 1996-12-04
EP0661061B1 (de) 2001-11-07
HK1048942A1 (zh) 2003-04-25
CA2139217A1 (en) 1995-06-30
EP0661061A2 (de) 1995-07-05
CA2139217C (en) 2001-08-07
CU22420A1 (es) 1996-01-31
DE69428969D1 (de) 2001-12-13
CN1099894C (zh) 2003-01-29
CN1371690A (zh) 2002-10-02
US5788985A (en) 1998-08-04
CN1122247A (zh) 1996-05-15
JP3044173B2 (ja) 2000-05-22
JPH0853366A (ja) 1996-02-27

Similar Documents

Publication Publication Date Title
DE69428969T2 (de) Impfstoff geeignet eine Immunantwort gegen N-Glycolysierte-Gangliosiden hervorzurufen und ihre Anwendung als Antikrebsmittel
IT8947832A0 (it) Tavolino plurivalente pieghevole per l'uso all'aperto, campeggio e simili
DE69228373T2 (de) Kosmetikum und emulsion
ATE211467T1 (de) 4-amino-derivate der mycophenolsäure mit immun suppressiver wirkung
DE69228492D1 (de) 3,4,N-Trisubstituierte-4,5-dihydro-1H-Pyrazol-1-carboxamide und deren Anwendung als Insektizide
FR2769915B1 (fr) Derives d'indazole tricycliques, leur preparation et leur application en therapeutique
DE69524871T2 (de) Benzopyrans und deren verwendung als therapeutische mittel
ATE183774T1 (de) Löslicher interferon-rezeptor, seine herstellung und anwendung
DE69526936D1 (de) Benzamide-derivate, zubereitungen die sie erhalten und ihre anwendung
DE69425210T2 (de) Cumarin derivate und deren anwendung
ATE226584T1 (de) 4-oxo-3,5-dihydro-4h-pyridazino(4,5-b)indol-1- acetamid-derivate, ihre herstellung und therapeutische anwendung
DE69024779D1 (de) Kern-Schale-Polymer und dessen Anwendung
DE58900054D1 (de) Fluessigkeitsreibungskupplung und deren anwendung.
DE69021304D1 (de) Vorbeugendes und therapeutisches Mittel gegen Hepatitis.
DE69203575D1 (de) Tertiäre cyclische Alkohole und ihre Anwendung als Riechstoffbestandteile.
DE68916634D1 (de) Alicyclische Ester und ihre Anwendung als Riechstoffkomponenten.
DE69330385D1 (de) Schützende antigene gegen eine (echinococcus granulosus) infektion und impfstoffe die entsprechende antigene enthalten
IT8919968A0 (it) Procedimento e composizione per ridurre la permeabilita' diuna zona ad alta permeabilita' in un giacimento petrolifero.
MX9205556A (es) Mejoras en composiciones novedosas que comprenden pentafluoroetano y monoclorodifluorometano.
IT217606Z2 (it) Dispositivo di bloccaggio in assetto d'uso della intelaiatura di un lettino pieghevole.
DE3874763T2 (de) In 14- und 15-stellung substituierte lanosterole und ihre anwendung als hypocholesterolemische mittel.
CH691791A8 (de) Pharmazeutische komposition gegen alkoholmissbrauch und mit notroper wirkung.
DE59010872D1 (de) Bindemittel, ihre Herstellung und Anwendung in härtbaren Mischungen
DE69317932T2 (de) Furanether und ihre Anwendung als Riechstoffe
DE69232238T2 (de) 3-halo-5-halomethyl-2-oxazolidinone-derivate und ihre anwendung als microbizide

Legal Events

Date Code Title Description
8364 No opposition during term of opposition